Notes: January 30, 2020 -- Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announced following approval of a reverse stock split range and authorized share reduction by stockholders at a special meeting of stockholders earlier today, Myomo’s Board of Directors determined to effect a reverse stock split of Myomo’s common stock at a ratio of one-for-thirty. The applicable Certificate of Amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended, was filed with the Delaware Secretary of State today and will become effective at 5:00 p.m. Eastern Time on January 30, 2020. Myomo’s common stock will begin trading on a split-adjusted basis when markets open on January 31, 2020. Myomo’s common stock will continue to trade on the NYSE American under the symbol “MYO,” although a new CUSIP number 62857J201 has been assigned to it as a result of the reverse stock split.